Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 13 · below the Ichimoku cloud · RSI 37 · MACD below its signal · 10% above its 52-week low
None of the 29 investors followed here reported a position in ACON in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ACON trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 16, 2026 | Sequira Amanda MaeDirector | Purchase at price 2.73 per share. | 5.9K | $15.99K |
| Aug 13, 2026 | Gould Gregory AChief Financial Officer | Purchase at price 2.45 per share. | 10K | $24.50K |
| Aug 12, 2026 | Wesemann William GDirector | Purchase at price 2.34 per share. | 2.1K | $5.03K |
| Aug 12, 2026 | Bond RyanDirector | Purchase at price 2.37 per share. | 21.1K | $50.06K |
| Aug 12, 2026 | Ness BrentChief Executive Officer | Purchase at price 2.31 per share. | 5.2K | $12.09K |
| Aug 12, 2026 | Neal David KDirector | Purchase at price 2.40 per share. | 7.5K | $18.00K |
| Jun 10, 2026 | Wesemann William GDirector | Stock Award(Grant) at price 0.00 per share. | 20K | — |
| Jun 10, 2026 | Gould Gregory AChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 50K | — |
| Jun 10, 2026 | Deitsch Stephen MDirector | Stock Award(Grant) at price 0.00 per share. | 20K | — |
| Jun 10, 2026 | Thramann Jeffrey JohnOfficer and Director | Stock Award(Grant) at price 0.00 per share. | 100K | — |
| Jun 10, 2026 | Bond RyanOfficer | Stock Award(Grant) at price 0.00 per share. | 55K | — |
| Jun 10, 2026 | Ness BrentChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 100K | — |
| Jun 10, 2026 | Neal David KDirector | Stock Award(Grant) at price 0.00 per share. | 20K | — |
| Jun 10, 2026 | Breidbart ScottDirector | Stock Award(Grant) at price 0.00 per share. | 20K | — |
| Jun 10, 2026 | Sequira Amanda MaeDirector | Stock Award(Grant) at price 0.00 per share. | 20K | — |
| May 11, 2026 | Breidbart ScottDirector | Purchase at price 3.18 per share. | 5.7K | $18.01K |
| May 10, 2026 | Ness BrentChief Executive Officer | Purchase at price 3.18 per share. | 6.3K | $20.00K |
| May 10, 2026 | Neal David KDirector | Purchase at price 3.10 per share. | 2.5K | $7.75K |
| May 5, 2026 | Wesemann William GDirector | Purchase at price 3.30 per share. | 1.6K | $5.16K |
| Nov 25, 2025 | Ness BrentChief Executive Officer | Purchase at price 6.20 per share. | 10 | $62 |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -28.0 | -17.2 | 19.3 | 1.5 | -1.2 | -12.2 | -21.9 | 4.4 | 2.6 | -11.2 | −53.5% | ||
| 2025 | -85.3 | -52.8 | -88.1 | -40.8 | 1.4 | 16.1 | -7.6 | 3.1 | 4.6 | 3.5 | -19.3 | -26.5 | −99.6% |
| 2024 | -25.0 | -83.4 | -17.1 | -9.1 | 0.0 | -4.7 | 10.1 | -33.7 | -12.4 | 0.5 | -2.2 | -20.0 | −95.5% |
| 2023 | 11.9 | 12.3 | -10.8 | -2.6 | 55.8 | -30.0 | -17.4 | -10.5 | -36.1 | 2.8 | -19.4 | -25.9 | −65.5% |
| 2022 | -39.1 | -27.5 | 6.1 | 14.4 | -29.9 | 37.5 | -28.0 | -24.7 | −72.0% |
Buy / hold / sell counts
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.